Molecular Profile | SMO E518K |
Therapy | Arsenic trioxide + Posaconazole |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Create By | tyin |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | SMO E518K | Advanced Solid Tumor | sensitive | Arsenic trioxide + Posaconazole | Preclinical | Actionable | In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO E522K (corresponding to human SMO E518K) in culture (PMID: 26823493). | 26823493 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(26823493) | Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma. | Full reference... |